StreetInsider.com News Articles

Repligen to Report Third Quarter 2026 Financial Results

Tue, 13 Oct 2026 07:30:00 -0400

WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended September 30, 2026.

The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 877042431. In addition, a webcast will

Repligen to Report Third Quarter 2026 Financial Results

Tue, 13 Oct 2026 07:30:00 -0400

The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 877042431. In addition, a webcast will

Form 4 REPLIGEN CORP For: Oct 06 Filed by: Douglass Brian Robb

Thu, 08 Oct 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20261008/27167443.html

Form SCHEDULE 13G/A REPLIGEN CORP Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27159978.html

Repligen (RGEN) PT Raised to $225 at Barclays

Wed, 07 Oct 2026 03:51:53 -0400

Barclays analyst Luke Sergott raised the price target on Repligen (NASDAQ: RGEN) to $225.00 (from $175.00) while maintaining a Overweight rating.

Form 4 REPLIGEN CORP For: Oct 05 Filed by: Loeillot Olivier

Tue, 06 Oct 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20261006/27155751.html

Form 8-K REPLIGEN CORP For: Oct 06

Tue, 06 Oct 2026 09:14:00 -0400

si-local-file:///var/storage/secattach/20261006/27153276.html

Repligen completes acquisition of BioLife Solutions for cash and stock

Tue, 06 Oct 2026 09:05:22 -0400

Repligen Corporation (NASDAQ: RGEN) announced it has completed its acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS), a developer and supplier of cell processing tools and services for the cell and gene therapy market, according to a press release dated Oct. 6, 2026.

Under the terms of the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash paid in lieu of any fractional shares.

BioLife's biopreservation media portfolio, led by its CryoStor product, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials.

"We are excited to welcome BioLife team

Repligen completes acquisition of BioLife Solutions for cash and stock

Tue, 06 Oct 2026 09:05:22 -0400

Under the terms of the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash paid in lieu of any fractional shares.

BioLife's biopreservation media portfolio, led by its CryoStor product, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials.

"We are excited to welcome BioLife team

Repligen Completes Acquisition of BioLife Solutions

Tue, 06 Oct 2026 09:05:00 -0400

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market.

“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin

Repligen Completes Acquisition of BioLife Solutions

Tue, 06 Oct 2026 09:05:00 -0400

Repligen Completes Acquisition of BioLife Solutions

Tue, 06 Oct 2026 09:05:00 -0400

Repligen Completes Acquisition of BioLife Solutions

Tue, 06 Oct 2026 09:05:00 -0400

Freshworks Set to Join S&P SmallCap 600